PF-4840154
From Infogalactic: the planetary knowledge core
200px | |
Names | |
---|---|
IUPAC name
4-Isobutylamino-2-[4-(tetrahydro-pyran-3-ylmethyl)-piperazin-1-yl]-pyrimidine-5-carboxylic acid benzylamide
|
|
Identifiers | |
ChEMBL | ChEMBL1818218 |
ChemSpider | 26610754 |
6309 | |
Jmol 3D model | Interactive image |
|
|
|
|
Properties | |
C26H38N6O2 | |
Molar mass | 466.63 g·mol−1 |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
verify (what is ?) | |
Infobox references | |
PF-4840154 is pyrimidine derivative discovered by Pfizer at its Sandwich, Kent research center. The compound is a potent, selective activator of both the human (EC50 = 23 nM) and rat (EC50 = 97 nM) TRPA1 channels. This compound elicits nociception in a mouse model through TRPA1 activation. PF-4840154 is used as a reference agonist of the TRPA1 channel for in-vitro High-throughput screening purposes, and is superior to allyl isothiocyanate for this use.[1] The TRPA1 channel is considered an attractive pain target based on the fact that TRPA1 knockout mice showed near complete attenuation of pain behaviors in some pre-clinical development models.[2][3]
References
Categories:
- Pages with broken file links
- Chemical articles without CAS Registry Number
- Articles without KEGG source
- Articles without UNII source
- Articles with changed InChI identifier
- Pages using collapsible list with both background and text-align in titlestyle
- Ion channels
- Pyrimidines
- Receptor agonists
- Pfizer
- Pyrans
- Piperazines